Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06494150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised
    v7
  2. 2 versions Re-verified since Feb 5, 2026, no change to tracked fieldsv5-v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2024 to Dec 26, 2024
    • Eligibility criteria expanded, about 10 words
    • Site details revised
    v4
  4. Start date: Oct 2024 to Dec 2024v3
  5. Start date: Aug 2024 to Oct 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).
Trial Details
NCT Number NCT06494150
Lead Sponsor University of Oklahoma
Collaborators: Aadi Bioscience, Inc.
Conditions
(from sponsor)		 Low Grade Ovarian Serous Adenocarcinoma
Related terms Ovarian Neoplasms
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov